Skip to main content
. 2020 Aug 8;28(12):2553–2563. doi: 10.1016/j.ymthe.2020.08.005

Figure 5.

Figure 5

MSC-C9 × T4 Treatment Enhances the Efficacy of PD-1 Blockade

(A) Scheme of MSC-C9 × T4 and anti-PD-1 antibody (αPD-1) treatment schedule. (B) Growth of CT26 tumors following treatments was recorded (n = 7–8 mice per group). (C) Survival rate of CT26 tumor-bearing BALB/c mice treated with engineered MSCs and αPD-1. ∗p < 0.05, ∗∗p < 0.01.